Takeda Pharmaceutical Company Limited
TAK · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.32 | -0.06 | 0.03 | -0.94 |
| FCF Yield | 4.77% | 2.01% | 2.46% | 5.13% |
| EV / EBITDA | 34.10 | 25.31 | 61.69 | 56.73 |
| Quality | ||||
| ROIC | -0.23% | 1.25% | -0.59% | 0.46% |
| Gross Margin | 65.85% | 65.24% | 63.73% | 63.56% |
| Cash Conversion Ratio | -32.25 | 1.73 | -2.15 | 16.13 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.06% | 2.89% | 4.39% | 5.10% |
| Free Cash Flow Growth | 131.84% | -19.04% | -48.81% | 46.30% |
| Safety | ||||
| Net Debt / EBITDA | 12.53 | 9.46 | 22.78 | 22.52 |
| Interest Coverage | 0.83 | 1.72 | -226.83 | 322.85 |
| Efficiency | ||||
| Inventory Turnover | 0.29 | 0.31 | 0.31 | 0.33 |
| Cash Conversion Cycle | 260.57 | 246.96 | 276.05 | 227.57 |